DNMT Inhibitors (DNA Methyltransferase Inhibitors)

Description

DNMT inhibitors block DNA methyltransferases (primarily DNMT1, DNMT3a, DNMT3b), preventing the addition or maintenance of methyl groups on cytosine residues. This generally leads to hypomethylation of target loci and, where methylation was repressing gene expression, to increased transcription.

Relevance to Psychiatry

Antidepressant Effects

Evidence (animal models):

Chronic social defeat stress increases Dnmt3a expression in NAc
- Overexpression of Dnmt3a in NAc increases depression-like behavior (via transcriptional repression)
- Intra-NAc infusion of RG108 (DNMT inhibitor): produces antidepressant-like effects in defeated mice
Zebularine (DNMT inhibitor, ICV): partially rescues the effect of maternal maltreatment-induced hypomethylation at BDNF promoter in PFC
- Note: in this context, the insult was hypomethylation, not hypermethylation; zebularine treatment direction of benefit requires interpretation caution

Proposed mechanism: Stress-induced Dnmt3a upregulation in NAc causes transcriptional silencing of genes needed for resilience. DNMT inhibition restores their expression.

Human evidence: DNMT expression is altered in limbic regions and brainstem of depressed suicide completers (Poulter et al. 2008). No clinical application established.

Schizophrenia and Epigenetic Targets

RELN and GAD1 promoter hypermethylation in SCZ suggests DNMT inhibition could partially restore expression — investigated preclinically
Antipsychotics differ in their ability to modify GABAergic promoter methylation
Clozapine has been suggested to affect DNA methylation patterns (separate literature, not covered in Nestler 2016)

Evidence Quality

Application	Evidence Level	Notes
Antidepressant via Dnmt3a inhibition in NAc	Moderate	Animal model; mechanism-specific
Reversing early-life stress epigenetic effects	Weak–Moderate	Context-dependent; some loci show hypomethylation as the problem
SCZ: restoring RELN/GAD1 expression	Weak	Preclinical hypothesis; no established treatment

Limitations and Concerns

Current DNMT inhibitors are nonspecific — affect DNA methylation genome-wide
Hypomethylation at some loci may be the problem (not hypermethylation), so blanket DNMT inhibition could worsen effects at those sites
Zebularine finding is paradoxical: maternal maltreatment causes hypomethylation at BDNF; DNMT inhibition still showed partial rescue — mechanism unclear
In oncology (approved uses), DNMT inhibitors (5-azacytidine, decitabine) have significant toxicity
No clinical trials for psychiatric indications

Side Effects

Genome-wide hypomethylation — unpredictable off-target effects
In oncology: myelosuppression, nausea, infection risk
Safety profile for CNS/psychiatric use is entirely unstudied